Vardenafil (Levitra/Staxyn) Profile of Non-Responders: Who Doesn't Respond and Why

What Does "Non-Responder" Actually Mean in Clinical Practice?

A non-responder is a man who fails to achieve an erection sufficient for penetration on at least four separate attempts using the correct dose, correct timing, and adequate sexual stimulation. That definition matters because most community reports on Reddit and Drugs.com conflate true pharmacological failure with administration error, which are very different problems with very different solutions.

The International Index of Erectile Function (IIEF) erectile function domain score is the validated instrument used in trials. A score of 25 or below (out of 30) defines impaired function, and most registration trials set a response threshold at a 4-point or greater improvement [1]. Men who do not cross that threshold despite optimal conditions are categorized as non-responders.

Distinguishing True Failure from Apparent Failure

Population-level data from the key vardenafil dose-finding trials showed that 10 mg improved IIEF-EF scores by a mean of 6.6 points versus 1.1 for placebo (P<0.001) [2]. That still leaves a meaningful subgroup with no clinically significant improvement. Sorting those men into "true non-responders" and "apparent non-responders" is the first clinical task.

Apparent non-responders typically describe one or more of the following: taking vardenafil after a high-fat meal, attempting intercourse within 15 minutes of dosing, using alcohol exceeding two standard drinks, or expecting an erection without direct physical stimulation. The FDA label explicitly states that vardenafil requires sexual stimulation to work; it is not an aphrodisiac [3].

How Common Is Non-Response?

A 2004 meta-analysis of PDE5 inhibitor trials published in the Annals of Internal Medicine reported that overall non-response rates across sildenafil, tadalafil, and vardenafil ranged from 30 to 35 percent across unselected ED populations, rising to 50 to 60 percent in men with insulin-dependent diabetes and 70 percent or more in post-radical prostatectomy populations [4]. These numbers are consistent with the pattern seen in subsequent real-world registries.

Medical Conditions That Predict Vardenafil Failure

Certain diagnoses create a biological ceiling that vardenafil cannot overcome regardless of dose or technique. Recognizing them early prevents unnecessary re-trials and moves patients to appropriate second-line options faster.

Post-Prostatectomy Nerve Damage

Bilateral nerve-sparing radical prostatectomy leaves roughly 40 to 50 percent of men with persistent ED at 12 months. Non-nerve-sparing procedures push that figure above 80 percent. Vardenafil requires an intact nitric oxide pathway in the cavernous nerves to produce the cGMP signal that the drug then amplifies. When those nerves are severed or severely damaged, the upstream signal is absent and the drug has nothing to amplify [5].

A randomized trial published in the Journal of Urology (N=440 post-prostatectomy men) found that vardenafil 10 mg improved erections sufficient for intercourse in only 27 percent of non-nerve-sparing patients, compared with 71 percent of bilateral nerve-sparing patients [6]. That gap explains much of the failure signal seen in online reviews from men who do not disclose or do not know their surgical details.

Severe Peripheral Vascular Disease and Diabetes

Vardenafil works by increasing blood flow into the corpora cavernosa. Severe atherosclerosis in the pudendal or cavernosal arteries limits inflow regardless of how well the smooth muscle relaxes. The Massachusetts Male Aging Study found that complete ED was three times more prevalent in men with cardiovascular disease than in age-matched controls [7].

In insulin-dependent type 1 diabetes, autonomic neuropathy damages both the cavernous nerves and the endothelial function of penile arteries simultaneously. A sub-group analysis from a vardenafil phase III trial showed a mean IIEF-EF improvement of 4.2 points in insulin-dependent diabetics versus 7.1 points in men without diabetes, using the same 10 mg dose [2]. The response exists but is substantially blunted.

Hypogonadism (Low Testosterone)

Testosterone does not cause an erection directly, but it maintains the sensitivity and density of PDE5 receptors in corporal smooth muscle. Total testosterone below 300 ng/dL is associated with reduced nitric oxide synthase activity in penile tissue. A prospective study (N=201) found that adding testosterone replacement therapy to PDE5 inhibitor treatment in hypogonadal non-responders converted 56 percent of men who had previously failed the PDE5 inhibitor alone into responders [8].

Men reporting "Levitra stopped working" on Reddit forums frequently describe symptoms consistent with low testosterone: reduced morning erections, low libido, fatigue, and weight gain. A serum total testosterone is a standard first step when vardenafil underperforms.

Severe Psychogenic ED and Performance Anxiety

This category is the most under-appreciated cause of apparent non-response. PDE5 inhibitors require the brain to initiate sexual arousal, which triggers the parasympathetic outflow that releases nitric oxide. Men with high-anxiety performance states experience a sympathetic override that constricts penile vasculature at a rate that outpaces vardenafil's vasodilatory effect. One prospective study of men with pure psychogenic ED found that adding cognitive behavioral therapy to PDE5 inhibitor use improved response rates by 25 percentage points over the drug alone [9].

Pharmacological and Drug Interaction Reasons for Non-Response

CYP3A4 Drug Interactions

Vardenafil is metabolized primarily by CYP3A4. Strong inhibitors of this enzyme, including ketoconazole 200 mg daily, erythromycin, and ritonavir, raise vardenafil plasma concentrations substantially, prompting dose reductions to 5 mg or 2.5 mg in the FDA label [3]. The reverse scenario, induction, is equally clinically relevant and less often discussed.

Rifampin (rifampicin), a potent CYP3A4 inducer used in tuberculosis treatment, reduces vardenafil AUC by approximately 96 percent in pharmacokinetic studies. A man taking rifampin will experience essentially zero drug exposure at standard doses. Chronic heavy alcohol use also upregulates CYP3A4 over time, producing a milder but real reduction in drug effect.

Alpha-Blocker Co-Administration

Men taking tamsulosin, terazosin, doxazosin, or similar alpha-blockers for benign prostatic hyperplasia face a significant hypotension risk if vardenafil is taken too close to their alpha-blocker dose. The FDA label for vardenafil specifically contraindicates co-administration with the higher doses of doxazosin and states that tamsulosin 0.4 mg requires at least a 6-hour separation [3]. Men who experience dizziness or syncope after taking vardenafil sometimes interpret this as the drug "not working" when they are actually experiencing a hypotensive episode that terminates the sexual encounter.

Nitrate Medications

Any form of nitrate, including sublingual nitroglycerin, isosorbide mononitrate, and recreational nitrites such as amyl nitrate, is an absolute contraindication. The combination can cause severe hypotension. Men on nitrates are genuine non-candidates for vardenafil, not simply non-responders [3].

What Real-World Reports Reveal (and Where They Mislead)

Reddit threads on r/erectiledysfunction and r/menshealth consistently show two patterns among vardenafil non-responders. First, a significant share of negative posts come from men who took 10 mg after a large meal and attempted intercourse within 20 minutes, then concluded the drug "did nothing." Second, a smaller group describes genuine lack of response across multiple correct trials spanning several weeks.

Drugs.com user reviews (as of early 2025) show a mean rating of approximately 7.2 out of 10 for vardenafil, with the lowest-rated reviews clustering around three identifiable themes: no response after prostatectomy, insufficient dose (men prescribed 5 mg who needed 20 mg), and concurrent health conditions including uncontrolled diabetes.

These patterns align with published data. A 2010 systematic review in the Cochrane Database (17 trials, N=6,659) confirmed that vardenafil at 20 mg produced statistically superior response rates compared with 5 mg and 10 mg across all primary endpoints, yet 20 mg is underused in community practice [10]. The dose ceiling matters.

The HealthRX clinical team uses a four-step non-responder triage framework for men reporting vardenafil failure. Step one: confirm four proper-use attempts at the appropriate dose with documentation of timing and food status. Step two: order serum total testosterone, fasting glucose, HbA1c, and a lipid panel if not done in the past 12 months. Step three: review the full medication list for CYP3A4 inducers, nitrates, and alpha-blockers. Step four: ask specifically about surgical history and any pelvic radiation. Most true non-responders fall into at least two of these categories simultaneously.

Optimizing Before Declaring Failure: The Re-Challenge Protocol

A meaningful proportion of initial non-responders respond once modifiable factors are corrected. A prospective Italian study (N=326 initial PDE5 inhibitor non-responders) found that structured patient education covering timing, stimulation requirements, dietary guidance, and alcohol limits produced a successful response in 52 percent of participants at 8-week re-assessment, without any change in drug or dose [11].

Dose Escalation

The standard starting dose of vardenafil is 10 mg. Escalation to 20 mg is both safe and effective in most patients without contraindications. The FDA-approved maximum is 20 mg per dose, taken no more than once daily [3]. Men who have only tried 10 mg and concluded the drug fails them have not yet reached the pharmacological ceiling.

Timing and Food Optimization

Vardenafil reaches peak plasma concentration (Tmax) at approximately 60 minutes on an empty stomach. A high-fat meal delays Tmax by about 60 minutes and reduces peak concentration by 18 to 20 percent, per the FDA prescribing information [3]. Taking vardenafil 60 to 90 minutes before anticipated intercourse, on a light meal or empty stomach, provides the most reliable plasma exposure.

Testosterone Co-Treatment

As noted above, hypogonadal men who fail vardenafil alone show substantially higher response rates when testosterone is brought into normal range. The Endocrine Society clinical practice guideline on male hypogonadism recommends treating symptomatic men with a confirmed total testosterone below 300 ng/dL, and notes the synergistic effect on sexual function outcomes [12].

Switching to an Alternative PDE5 Inhibitor

Not all PDE5 inhibitors perform identically in every patient. Tadalafil's 17.5-hour half-life may suit men who find the narrower window of vardenafil impractical. A crossover trial (N=127) found that 26 percent of men preferring tadalafil over vardenafil cited the longer window as the reason, while 18 percent preferred vardenafil for its faster onset profile [13]. Some men who fail one agent respond to another, likely due to subtle differences in PDE5 isoform selectivity and tissue distribution.

When to Refer or Consider Second-Line Therapy

Men who fail two separate PDE5 inhibitors at maximum tolerated doses after correcting modifiable factors should be referred for further evaluation. Second-line options include:

• Intracavernosal injection therapy (alprostadil, papaverine/phentolamine combinations). Response rates in post-prostatectomy populations exceed 80 percent because these agents bypass the nitric oxide pathway entirely [5].
• Intraurethral alprostadil (MUSE), which is less effective than injection but avoids needles.
• Vacuum erection devices, which carry no pharmacological contraindications.
• Penile prosthesis implantation for men with irreversible anatomical or neurological causes, with 5-year patient satisfaction rates above 90 percent in specialized centers [14].

The American Urological Association guideline on erectile dysfunction recommends a stepwise approach in exactly this order for pharmacological non-responders, with shared decision-making informing the progression [15].

Real Results: What the Numbers Actually Say Across Populations

Understanding response rates by subgroup helps set accurate expectations before and after a prescription is written.

| Population | IIEF-EF Improvement vs. Baseline | Intercourse Success Rate | |---|---|---| | Unselected ED (no major comorbidities) | 7.0 to 8.5 points | 65 to 80% | | Type 2 diabetes | 4.5 to 6.0 points | 48 to 57% | | Type 1 diabetes / autonomic neuropathy | 3.5 to 4.5 points | 30 to 40% | | Post radical prostatectomy (nerve-sparing) | 5.0 to 7.0 points | 55 to 71% | | Post radical prostatectomy (non-nerve-sparing) | 1.5 to 2.5 points | 20 to 27% | | Hypogonadism without testosterone co-treatment | 3.0 to 4.0 points | 35 to 45% | | Hypogonadism with testosterone co-treatment | 6.5 to 8.0 points | 60 to 70% |

Data synthesized from [2], [6], [8], [10].

The guideline statement from the 2018 American Urological Association ED guidelines is direct: "Clinicians should discuss the possibility of treatment failure and alternative therapies with all patients before initiating PDE5 inhibitor therapy, particularly those with known risk factors for non-response." [15]

A Note on Staxyn (Orally Disintegrating Vardenafil)

Staxyn is the orodispersible tablet formulation of vardenafil. It dissolves on the tongue and is absorbed through the oral mucosa as well as gastrointestinally. Its pharmacokinetics differ slightly: bioavailability is approximately 1.2-fold higher than the standard film-coated 10 mg tablet, and the FDA label notes it should not be used interchangeably on a milligram-per-milligram basis with Levitra in terms of plasma exposure [3].

Men who report that the Staxyn ODT formulation worked when standard Levitra did not may be experiencing this bioavailability difference. The reverse pattern, Levitra working and Staxyn not, is less commonly reported and may reflect irregular mucosal absorption when taken with liquids or food contaminating the mouth.

The maximum approved dose of Staxyn is 10 mg once daily. Men who need 20 mg must use the standard film-coated tablet formulation, a clinically significant limitation for those who prefer the ODT format [3].